Isocitrate Dehydrogenase (IDH) Inhibitors Market Trends Report 2025 – For Business Development and Strategy Teams
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#What Is the Forecast for the Isocitrate Dehydrogenase (IDH) Inhibitors Market Growth in 2025?#_x000D_
The market size for isocitrate dehydrogenase (idh) inhibitors has witnessed an exponential surge in the recent past. It is projected to increase from $1.94 billion in 2024 to $2.46 billion in 2025, with a compound annual growth rate (CAGR) of 27.0%. The growth observed in the previous period is largely due to increased instances of hematologic cancers, advancement in genetic profiling in oncology, the successful outcomes of targeted therapies, initiatives in precision medicine, and an upsurge in healthcare expenditure in the field of oncology._x000D_
_x000D_
#What Is the Forecast for the Isocitrate Dehydrogenase (IDH) Inhibitors Market Size Through 2029?#_x000D_
The isocitrate dehydrogenase (idh) inhibitors market is projected to experience an upward trend, growing to $6.34 billion by 2029, with a compound annual growth rate of 26.7%. Certain factors attribute to this predicted growth such as favorable reimbursement policies, escalation in blood cancer cases, heightened awareness of oncologists, the increasing use of precision medicine, and enhancement in healthcare infrastructure and oncology centers. Significant trends that can be observed during the forecast period include progress in genomic and molecular diagnostics, partnerships and licensing agreements, drug delivery technology developments, enhancements in diagnostic technologies, and the evolution of combination therapies._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=24577&type=smp_x000D_
_x000D_
#What are the Key Market Players in Isocitrate Dehydrogenase (IDH) Inhibitors Market and How They’re Evolving?#_x000D_
Major companies operating in the isocitrate dehydrogenase (IDH) inhibitors market are Roche Holding AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology, Inc., Philogen S.p.A., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC_x000D_
_x000D_
#What Are the Primary Growth Drivers in the Isocitrate Dehydrogenase (IDH) Inhibitors Market?#_x000D_
The projection of a surge in Acute Myeloid Leukemia (AML) occurrences is anticipated to catalyze the expansion of the Isocitrate Dehydrogenase (IDH) inhibitors market. AML corresponds to a rapidly progressing cancer of the blood and bone marrow, signified by an abnormal overproduction of white blood cells that disrupt regular blood cell development. The escalation in AML instances can be attributed to the growing elderly demographic, as they confront an increased risk of acquiring this aggressive form of blood cancer due to age-induced modifications in their bone marrow and immune system. IDH inhibitors offer a remedial solution for AML by impeding the function of mutant IDH enzymes, thus enabling regular blood cell growth and restraining leukemia cell multiplication. The Leukaemia Foundation of Australia published a report in February 2023 stating that, within the timeframe of 2022 to 2035, an estimated 7,000 children, 6,000 young adults, and 108,000 adults between the ages of 25 to 65 are projected to be diagnosed with blood cancers majorly constituting of Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), and Non-Hodgkin Lymphoma (NHL). Hence, the predicted acceleration in AML instances is slated to boost the growth of the Isocitrate Dehydrogenase (IDH) inhibitors market._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=24577&type=smp_x000D_
_x000D_
#What Are the Leading Segments in the Global Isocitrate Dehydrogenase (IDH) Inhibitors Industry?#_x000D_
The isocitrate dehydrogenase (IDH) inhibitors market covered in this report is segmented –_x000D_
_x000D_
1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types_x000D_
2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types_x000D_
3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical_x000D_
4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications_x000D_
_x000D_
Subsegments:_x000D_
1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma_x000D_
2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)_x000D_
3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers_x000D_
_x000D_
#What Are the Key Market Trends in the Isocitrate Dehydrogenase (IDH) Inhibitors Industry?#_x000D_
Leading firms in the isocitrate dehydrogenase (IDH) inhibitors market are concentrating on securing regulatory clearances to broaden the clinical application of their treatments, expedite their entry into the market, and establish a competitive edge in addressing IDH-mutant cancers. Regulatory clearances are official endorsements given by health authorities that allow a medicine to be marketed and used, following verification of its safety and efficacy. For instance, Servier Laboratoires, a pharmaceutical company based in France, obtained FDA approval for its VORANIGO (vorasidenib) tablets in August 2024. This was the first targeted therapy for Grade 2 IDH-mutant glioma patients, including those with astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. The Phase 3 INDIGO trial revealed these tablets significantly increased progression-free survival, where patients showed a median progression-free survival of 27.7 months, in contrast to 11.1 months on a placebo. VORANIGO provides a manageable and well-tolerated alternative with manageable side effects, representing a remarkable progress for a patient group who had few previous treatment options._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#What Is the Regional Outlook for the Isocitrate Dehydrogenase (IDH) Inhibitors Market?#_x000D_
North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (IDH) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24577_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the isocitrate dehydrogenase (idh) inhibitors market, and how is it changing globally?_x000D_
2. Who are the major companies in the isocitrate dehydrogenase (idh) inhibitors market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the isocitrate dehydrogenase (idh) inhibitors market right now?_x000D_
4. Which products or customer segments are growing the most in the isocitrate dehydrogenase (idh) inhibitors market?_x000D_
5. What factors are helping or slowing down the growth of the isocitrate dehydrogenase (idh) inhibitors market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 3156230293_x000D_
Asia +44 2071930708_x000D_
Europe +44 2071930708_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
